Health & Biotech Biotech New Prescient leadership to drive PTX-100 development in rare blood cancer
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...
One in five people will get cancer in their lifetime – almost everyone has been...
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...
Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, aggressive...
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a...
PTX-100 targets high-mortality cancers linked to RAS mutations.

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.